Revenue Breakdown
Composition ()
No data
Revenue Streams
ASP Isotopes Inc (ASPI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specialist isotopes and related services, accounting for 81.0% of total sales, equivalent to $3.39M. Other significant revenue streams include Helium and LNG and Nuclear fuels. Understanding this composition is critical for investors evaluating how ASPI navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, ASP Isotopes Inc maintains a gross margin of 39.86%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -595.41%, while the net margin is -638.90%. These profitability ratios, combined with a Return on Equity (ROE) of -116.50%, provide a clear picture of how effectively ASPI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ASPI competes directly with industry leaders such as LXRX and SPTX. With a market capitalization of $844.81M, it holds a significant position in the sector. When comparing efficiency, ASPI's gross margin of 39.86% stands against LXRX's 99.49% and SPTX's N/A. Such benchmarking helps identify whether ASP Isotopes Inc is trading at a premium or discount relative to its financial performance.
